SAN DIEGO, Aug. 21, 2017 /Weed Wire/ — Medical Marijuana, Inc. (MJNA), the first publicly traded cannabis company in the United States, today announced that the State of Mexico’s government has purchased the company’s Real Scientific Hemp Oil-X™ (RSHO-X™) CBD hemp oil products from its subsidiary HempMeds Mexico® to treat 11 of its citizens suffering from varying indications including Refractory Epilepsy and Lennox Gastaut-Syndrome. This is the first time a government in Mexico has purchased CBD products for its citizens.
The State of Mexico’s Governor Eruviel Avila distributed HempMeds Mexico’s flagship product RSHO-X™, a CBD hemp oil with zero THC, to the patients at the inauguration of a new clinic located in Ecatepec on August 17th.
“We want to congratulate the State of Mexico’s government for this historic purchase of
our RSHO CBD products to help improve the lives of its citizens,” said Medical Marijuana, Inc. Dr. Stuart Titus. “We are a Company of firsts, including having the first and only federally legal CBD product in Mexico and we are excited about this new historic milestone of being the first Company that the Government of Mexico has contracted to purchase and pay for cannabinoid CBD products to benefit its citizens.”
“The plethora of benefits of cannabinoids (botanical as well as pharmaceutically developed) in treating multiple indications is now being researched and we are encouraged to see significant anecdotal evidence leading the way,” added Dr. Titus. “Now, health care professionals and government health care agencies are becoming increasingly interested in how CBD hemp oil can help benefit many medical conditions, especially those conditions where conventional medicine has had modest effects.”
Dr. Saul Garza Morales, pediatric researcher and neurologist in Mexico, recently shared the positive results of a recent study he conducted on the effects of Medical Marijuana, RSHO-X™ product in treating children with severe epilepsy, in which 86 percent of the 29 patients he studied experienced statistically significant (greater than 50%) reduction in motor seizures. Seventeen percent of the children were fully seizure free for a 4-month period.
HempMeds® Mexico is the first company to receive government import permits for a cannabis product via approval by the Mexican Health Department, COFEPRIS. With these achievements and other firsts in Latin American countries like Brazil where HempMeds Brasil™ became the first company to offer legal medicinal cannabis products to Brazil after receiving import approval and Paraguay where RSHO™ was the first medical cannabis product approved for import into the country. Medical Marijuana Inc. and the company’s subsidiaries have become a leader in the Latin America cannabis industry by providing products to help those suffering from various conditions including:
*Amyotrophic Lateral Sclerosis
About HempMeds® Mexico
HempMeds® Mexicois a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at: http://www.hempmeds.mx.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here.
Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.